NCT07220616

A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies

A Phase 1/2, Multicenter, Open-Label, Multi-Cohort, First-in Human Trial of DS3790a, for Hematological Malignancies

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 420 (estimated)
• Sponsor: Daiichi Sankyo · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This clinical trial is designed to assess the safety, preliminary efficacy, and pharmacokinetics (PK) of DS3790a monotherapy and combination regimens in participants with hematological malignancies.

Detailed description

DS3790a may be effective in the treatment of patients with hematological malignancies. The primary objective of this study will assess the safety and preliminary efficacy of DS3790a monotherapy and combination regimens.

Conditions

• Hematological Malignancies

Interventions

Type	Name	Description
DRUG	DS3790a	Administered as specified in the protocol
DRUG	Combination drug	Administered as specified in the protocol
DRUG	Combination drug	Administered as specified in the protocol

Timeline

• Start date: 2026-01-16
• Primary completion: 2030-11-30
• Completion: 2030-11-30
• First posted: 2025-10-24
• Last updated: 2026-03-18

Locations

4 sites across 2 countries: United States, Japan

Regulatory

• FDA-regulated drug study